Home → News
Statement on Prescribing Chloroquine, Hydroxychloroquine, and Azithromycin
Click Here To See A Statement For Prescribing, Approved by the Board on April 16, 2020Important Change Regarding Buprenorphine Use
Recent Change to DEA Registration Requirements Regarding Use of Buprenorphine for Treatment of Opioid Use Disorder
On December 29, 2022, the Drug Enforcement Administration DATA-Waiver registration was eliminated. All licensees should be aware of the following:
A DATA-Waiver registration ("X-Waiver") is no longer required to treat patients with buprenorphine for opioid use disorder.
Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
There are no longer any limits on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
Currently, certain provisions of joint Board rules Chapter 12 Joint Rule Regarding Office Based Treatment of Opioid Use Disorder and Chapter 21 Use of Controlled Substances for Treatment of Pain are in conflict with these changes to the DEA registration requirements. Consequently, the Board will not investigate alleged violations associated with the DEA registration requirement changes retroactive to December 29, 2022.
Furthermore, the Board will initiate joint rulemaking regarding Chapter 12 and Chapter 21 to make them consistent with the changes to the DEA registration requirements
Statement of the Maine State Board of Nursing on IV Therapy Clinics
PDFFraud Detection Guidance for Employers and Educators
Fraud Detection Guidance for Employers and Educators - PDFBoard Opportunity
The Board has a vacancy for a Public Member.
If you are interested in this opportunity, please contact the Board's Executive Director, Kim Esquibel, PhD, MSN, RN, at (207) 287-1148 or e-mail at kim.esquibel@maine.gov
